81 results
8-K
ATXI
Avenue Therapeutics Inc
15 Mar 24
Other Events
7:15am
the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it was not in compliance
424B3
ATXI
Avenue Therapeutics Inc
2 Feb 24
Prospectus supplement
12:00am
, unless such holder enters into an agreement with the U.S. Department of Treasury to collect and provide substantial information regarding its U.S
8-K
ATXI
Avenue Therapeutics Inc
24 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1:19pm
Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) granted the Company an extension through November 15, 2023, to regain compliance
8-K
EX-99.2
yggqux676jtnt1c0
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-99.1
0y6a364
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-10.2
fxdc1lbnq3etr
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
nlp8r71od610hs vzm
2 Nov 23
Prospectus supplement with pricing info
9:00am
8-K
w80f4e1 550p
28 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:25pm
8-K
wb65jptkbf
21 Jul 23
Other Events
4:37pm
424B3
wkogjjwjl8y i6imat
28 Jun 23
Prospectus supplement
4:56pm
8-K
5agvi4k446rt2
22 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:07pm